Clinical Trial Update: A Study to Compare Efficacy, Pharmacokinetics, Safety and Immunogenicity of MB04 [proposed Etanercept Biosimilar] to Enbrel® [EU-sourced] in Rheumatoid Arthritis [Phase 3]

View source ↗

Summary

This is a Phase 3 trial update comparing MB04, a proposed etanercept biosimilar, to Enbrel in rheumatoid arthritis, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• ENBREL (etanercept)
• MB04 (MB04)

Snippet

Sponsor: mAbxience Research S.L. | Conditions: Rheumatoid Arthritis (RA) | Phase 3 | Status: RECRUITING